secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-07-23T23:59:59+00:00
Accession:  0001140361-24-033856
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio appoints Thomas Trimarchi as President and COO; Neil Kumar remains CEO
--------------------------------------------------------------------------------

- Thomas Trimarchi appointed President and COO effective July 23, 2024; Neil Kumar steps down as President but stays CEO and director.
- Trimarchi previously served as Chief Product Officer since 2018; also board member of affiliate ML Bio Solutions (BBP-418 for LGMD2I/R9).
- Newly created role to drive operational excellence, strategic planning, and centralize late-stage pipeline operations.
- Trimarchi holds a Ph.D. in Molecular Oncology and Immunology from NYU; prior roles at Regeneron and Goldman Sachs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/0001140361-24-033856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/ef20032871_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-033856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer